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Runt-related transcription factor 3a b s t r a c t
Multidrug resistance (MDR) is the main barrier to the success of chemotherapy for gastric cancer
(GC). miR-106a, which is highly expressed in GC, inﬂuences a variety of aspects of GC. However,
the function of miR-106a in MDR of GC still remains unclear. In the present study, we found that
miR-106a is elevated in MDR cell lines. miR-106a promotes chemo-resistance of GC cells, accelerates
ADR efﬂux, and suppresses drug-induced apoptosis. Finally, we show that runt-related trans factor 3
(RUNX3) is the functional target of miR-106a. Collectively, these ﬁndings demonstrate that miR-
106a may promote MDR in GC cells by targeting RUNX3.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer (GC) is the second most common cause of death
from cancer in the world, and little improvement in long-term sur-
vival has been achieved over decades [1]. Though chemotherapy is
the most common treatment for GC, multidrug resistance (MDR)
limited the effect of chemotherapy, which is caused by the devel-
opment of resistance to multiple chemo-therapeutic agents [2].
Multiple mechanisms have been suggested to account for MDR,
involving extrusion of the drug uptake, increased efﬂux, increased
DNA damage repair, suppression of apoptosis and other cell func-
tions [3,4]. However, the precise underlying mechanisms of MDR
have not been fully elucidated. Recently, microRNAs (miRNAs)
have been proposed to play essential roles in the development of
MDR [5].
miRNAs are a class of small non-coding RNAs which bind to the
30 untranslated regions (30 UTRs) of mRNAs, inhibiting translation
or inducing mRNA degradation [6]. miRNAs played critical roles
in the regulation of various biological processes such as apoptosis,
proliferation, and migration [7]. Emerging evidences have sug-
gested that the drug-induced deregulation of miRNAs might mod-
ulate MDR in cancer cells, and several studies have shown that
elevation/inhibition of miRNAs expression could modulate MDR
in cancer cells [8,9].miR-106a, belonging to the miR-17 family, was increased in
many cancers, including colorectal cancer [10], T lymphocyte tu-
mor [11], and GC [12]. Wang et al., reported that miR-106a could
inhibit extrinsic apoptotic pathway in GC cells by targeting Focal
Adhesion Kinase (FAS) [12]. Xiao et al. also reported the clinical sig-
niﬁcance of miR-106a in GC [13]. However, the role of miR-106a in
the development of MDR in human GC cells and the underlying
mechanism remain unclear.
Herein, we observed that miR-106a was increased in two MDR
human GC cell lines. We found that overexpression of miR-106a
decreased GC cell sensitivity to anticancer drugs. Moreover,
miR-106a promoted MDR in GC cells by promoting the efﬂux of
chemo-therapeutic drugs and suppressing drug-induced apoptosis.
More importantly, we demonstrated that miR-106a might play an
essential role in the development of MDR in human GC cells by
targeting runt-related transcription factor 3 (RUNX3).
2. Materials and methods
2.1. Cell lines and culture
The SGC7901 human gastric adenocarcinoma cell line was pur-
chased from Academy of Military Medical Science (Beijing, China)
and the MDR variants SGC7901/ADR and SGC7901/VCR (estab-
lished and maintained in our laboratory) were maintained in RPMI
1640 medium (Invitrogen, CA, USA) supplemented with 10% fetal
calf serum (Invitrogen) in a humidiﬁed atmosphere containing 5%
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mycin (ADR, 0.4 lg/ml) and vincristine (VCR, 1 lg/ml) were added
to the culture media of SGC7901/ADR and SGC7901/VCR cells,
respectively.
2.2. RNA extraction and quantitative real time PCR (qRT-PCR)
miRNAs were extracted using a miRNA Extraction Kit (Tiangen,
Beijing, China). Poly (A) was added, and 1 lg RNA containing
miRNAs was reversely transcribed into cDNA for the detection of
miR-106a. Primers of miR-106a and U6 were obtained from
GeneCopoeia (MD, USA). To detect RUNX3 expression, total RNA
was extracted using Trizol (Invitrogen), and was further reversely
transcribed into cDNA using a reverse transcription kit from
TOYOBO (Tokyo, Japan). The expression of miRNA or RUNX3 was
assayed using SYBR Premix Ex Taq from Takara (Dalian, China) in
a Stepone plus system (Invitrogen). The qRT PCR primers used
were as follows: MDR1-forward 50-GCCTAATGCCGAACACA-30,
MDR1-reverse 50-TCCTGGGACACGATGCC-30; GAPDH-forward 50-G
GTGGTCTCCTCTGACTTCAACA-30, and GAPDH-reverse 50-GTTGCTG
TAGCCAAATTCGTTGT-30. U6 or GAPDH was used as endogenous
control.
2.3. Plasmids and transfection
The miR-106a mimic/inhibitor and corresponding control were
obtained from RiboBio (Guangzhou, China). pBK-RUNX3 was
kindly gift by Dr. J. Farrell, from Ludwig Institute for Cancer Re-
search. Target cells were transfected with miR-106a mimic/inhibi-
tor or the corresponding control (150 nM) using Lipofectamine
2000 (Invitrogen), and cells were collected 48 h after transfection.
2.4. In vitro drug sensitivity assay
Cells were seeded into 96-well plates (8  103 cells/per well)
and maintained overnight. ADR, VCR, cisplatin (CDDP), and 5-ﬂuo-
rouracil (5-FU), were freshly prepared before experiment. Cells
were incubated for 24 h with/without these chemo-therapeutic
drugs. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide (MTT) was added to each well, and cells were incubated for
another 4 h. The absorbance at 490 nm (A490) was read on a
microplate reader. 50% inhibition of growth (IC50) of each drug
was estimated by the relative survival curve. Three independent
experiments were performed in quadruplicate.
2.5. Cell apoptosis assays
24 h after transfection, cells were further incubated with che-
mo-therapeutic drugs including CDDP, and 5-FU for 48 h. Then,
cells were collected, and the Annexin V-FITC Apoptosis Detection
Kit (BD Biosciences, NY, USA) was used for apoptosis assays. Cells
were washed twice with cold PBS, and then 5 lL Annexin V-FITC
and 10 lL propidium iodide were added to these cells. After incu-
bation for 15 min at 25 C, 400 lL Annexin-binding solution was
added to each well, and samples were kept on ice for counting
the stained cells by ﬂow cytometry. Data were analysed using
ModFit (BD Biosciences). Experiments were performed in
triplicate.
2.6. Analysis of intracellular ADR concentrations
Fluorescence intensity of intracellular ADR was detected by
ﬂow cytometry as described previously [14]. Brieﬂy, cells were
seeded into 6-well plates (1  106 cells/per well) and cultured
overnight at 37 C. ADR (5 lg/ml) was added to cultures, and cells
were further incubated for 1 h. Cells were then either collected todetect ADR accumulation or cultures were kept in a drug-free med-
ium for another 2 h, followed by measurement of ADR retention.
Fluorescence intensity of intracellular ADRwas detected using ﬂow
cytometry with an excitation wavelength of 488 nm and emission
wavelength of 575 nm. The ADR release index was calculated
according to the following formula: releasing index = (accumula-
tion value  retention value)/accumulation value. Experiments
were performed in triplicate.
2.7. Western blot
Cells were harvested at 48 h after transfection and homoge-
nised in lysis buffer (Beyotime, Shanghai, China). The extracts were
separated by 10% SDS–PAGE gel, transferred to a polyvinylidene
diﬂuoride membrane (Millipore, MA, USA). The membrane was
probed with primary antibodies speciﬁc to Bcl-2 (1:1000,
ab18210, Abcam, Cambridge, UK), Bax (1:1000, ab32503, Abcam),
P-gp (1:500, ab10333, Abcam), RUNX3 (1:1000, ab40278, Abcam),
GAPDH (1:1000, G9545, Sigma–Aldrich, MO, USA). The membranes
were incubated with horseradish peroxidase-conjugated second-
ary antibody (1:2000, Sigma–Aldrich). Bands were detected using
an ECL kit (Pierce, IL, USA). Experiments were performed in
triplicate.
2.8. Luciferase reporter assays
The wild-type or mutated human RUNX3 30 UTR sequence con-
taining potential binding sites, nucleotides 2076–2082 of the
RUNX3 30 UTR, was ampliﬁed with the primers 50-CCCTCGAGTGG-
CAGGTTAGGCAGTC-30 (sense) and 50-TTGCGGCCGCCAGGATCAG-
GAAGGGT-30 (antisense), and cloned into the psiCHECK-2 vector
within the XhoI/NotI cloning sites (Promega, WI, USA). SGC7901
cells were transfected with a mixture of 0.02 lg psiCHECK-2-
RUNX3 and 150 nM miR-106a mimic. Fly luciferase was used as
control. Renilla and ﬁreﬂy luciferase activity was detected using
the Dual-Luciferase Reporter Assay System (Promega).
2.9. Statistical analysis
Statistical analyses were performed using SPSS 16.0 software
(SPSS, IL, USA). Data were presented as the mean ± S.E.M. The dif-
ference was analysed with Student’s t test. Differences were con-
sidered signiﬁcant when P < 0.05.
3. Results
3.1. miR-106a was increased in MDR GC cells
To determine whether miR-106a was involved in the develop-
ment of MDR in GC cells, we performed qRT PCR in MDR GC cells
SGC7901/ADR and SGC7901/VCR, and the parental cell line
SGC7901. We found that miR-106a was increased in both
SGC7901/ADR and SGC7901/VCR cells compared with SGC7901
cells (Fig. 1A). Effect of miR-106a mimic was determined in
SGC7901 cells, which signiﬁcantly increased miR-106a expression
(Fig. 1B). Effect of miR-106a inhibitor was found to suppress miR-
106a expression remarkably (Fig. 1C). Our results suggested that
miR-106a might be involved in MDR of GC cells.3.2. miR-106a suppressed the sensitivity of GC cells to anticancer drugs
To investigate whether miR-106a had a direct function in the
development of MDR in GC, we studied SGC7901 or SGC7901/
VCR cells transfected with miR-106a mimic or inhibitor. MTT assay
revealed that SGC7901 cells transfected with miR-106a mimic
Fig. 2. miR-106a suppressed the sensitivity of GC cells to anticancer drugs. SGC7901 cells were transfected with miR-106a or the control mimic, and incubated with three
chemo-therapeutic drugs for 72 h. MTT assay was used to assess cell viability, and the IC50 values were calculated (A). SGC7901/VCR cells were transfected with miR-106a or
the control inhibitor, and incubated with three chemo-therapeutic drugs for 72 h. MTT assay was used to assess cell viability, and the IC50 values were calculated (B). Data
were obtained in three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control group.
Fig. 1. miR-106a was increased in MDR GC cells. The expression levels of miR-106a in GC cells were examined by qRT-PCR. U6 was used as control (A). SGC7901 cells were
transfected with miR-106a mimic (150 nM). Expression of miR-106a was detected by qRT-PCR at 48 h after transfection (B). SGC7901/VCR cells were transfected with miR-
106a inhibitor (150 nM). Expression of miR-106a was detected by qRT-PCR at 48 h after transfection (C). Data were obtained in three independent experiments. ⁄⁄P < 0.01
compared with control group.
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indicated by substantially increased IC50 values (Fig. 2A). In con-
trast, suppression of the miR-106a level in SGC7901/VCR cells re-
sulted in an enhanced sensitivity to ADR, CDDP, and 5-FU
(Fig. 2B). These data indicated that modulation of miR-106a
expression altered the sensitivity of GC cells to chemo-therapeutic
drugs.
3.3. miR-106a promoted the efﬂux of ADR via P-gp upregulation
To explore the role of miR-106a in drug efﬂux of GC cells, we
detected ADR release index in SGC7901 cells transfected with
miR-106a mimic. The efﬂux of ADR was clearly enhanced after
miR-106a mimic transfection (Fig. 3A). Consistent with ADR
release index, qRT PCR demonstrated increased Multi Drug Resis-
tance Protein 1 (MDR1) mRNA level (Fig. 3B) and elevated P-glyco-
protein (P-gp) protein level, which was encoded by MDR1 gene, in
miR-106a mimic transfected SGC7901 cells (Fig. 3C and D). To
further investigate whether miR-106a promoted MDR in GC cells
by increasing P-gp level and promoting the drug efﬂux, we treated
the transfected SGC7901 cells with the P-gp inhibitor verapamil.
Verapamil supplement decreased ADR release index of SGC7901
cells transfected with miR-106a mimic (Fig. 3E). In contrast,
miR-106a inhibitor transfection in SGC7901/ADR cells signiﬁcantly
decreased ADR release index compared with SGC7901/ADR cells
transfected with the control inhibitor (Fig. 3F). These results
indicated that miR-106a might accelerate the efﬂux of ADR via
P-gp upregulation.3.4. miR-106a suppressed drug-induced apoptosis
We further investigated the effect of miR-106a on the drug-in-
duced apoptosis of GC cells. Apoptosis of miR-106a mimic transfec-
ted GC cells after incubation with CDDP and 5-FU was measured.
Flow cytometry showed that the apoptosis percentage of cells after
CDDP incubation signiﬁcantly decreased in SGC7901 cells transfec-
ted with miR-106a mimic (Fig. 4A). Similar results were observed
in cells incubated with 5-FU (Fig. 4B). Moreover, Western blot
revealed the elevation of Bcl-2 together with the inhibition of
Bax in SGC7901 cells transfected with miR-106a mimic (Fig. 4C
and D). These results suggested that miR-106a could suppress
SGC7901 cells’ susceptibility to the drug-induced apoptosis.3.5. miR-106a modulated MDR by targeting RUNX3
miRNA target analysis tool TargetScan 6.2 was used to screen
potential target of miR-106a. RUNX3 was predicted to be a target
of miR-106a (Fig. 5A). To validate targeting of RUNX3 by miR-
106a, we performed luciferase activity assay. The wild-type RUNX3
30 UTR (WT) luciferase reporter plasmid or the mutated (Mut) was
cotransfected with miR-106a mimic or the control mimic into
SGC7901 cells. The cotransfection of miR-106a mimic with WT in
SGC7901 cells showed remarkably decreased luciferase activity
compared with the control mimic group, while Mut luciferase
activity was not changed (Fig. 5B). Transfection of miR-106a mimic
in SGC7901 cells signiﬁcantly decreased the protein level of RUNX3
Fig. 3. miR-106a promoted the efﬂux of ADR via P-gp upregulation. The ADR release index of miR-106a mimic transfected SGC7901 cells was detected after incubation with
5 lg/ml ADR for 24 h (A). Expression of MDR1 in miR-106a mimic transfected SGC7901 was examined by qRT-PCR 48 h after transfection (B). The expression of P-gp in miR-
106a mimic transfected SGC7901 was detected by Western blot 48 h after transfection. (C and D). SGC7901 cells were transfected with miR-106a mimic supplement with or
without verapamil (2.5 lg/ml) and then incubated with 5 lg/ml ADR for 24 h, and ADR release index was calculated (E). SGC7901/ADR cells were transfected with miR-106a
inhibitor and treated as in Fig. 3E, and ADR release index was calculated (F). Data were obtained in three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control
group.
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To explore whether RUNX3 mediated the function of miR-106a,
we detected the protein levels in MDR GC cells SGC7901/ADR and
SGC7901/VCR, and the parental cell line SGC7901. We found that
RUNX3 was signiﬁcantly decreased in both SGC7901/ADR and
SGC7901/VCR cells compared with SGC7901 cells (Fig. 5D). More-
over, we found that RUNX3 overexpression could reverse the effect
of miR-106a on the sensitivity of GC cells to anticancer drugs
(Fig. 5E). These results suggested that miR-106a might induce
MDR in GC cells by inhibiting RUNX3 expression.4. Discussion
MDR is one of the most common causes of treatment failure in
GC chemotherapy. Recently, several studies have identiﬁed numer-
ous miRNAs involved in the development of MDR in GC [15–19].
Our present data also demonstrated that miR-106a, one of the
most important pro-oncogenic component of the miR-106a363
cluster [10,20], could regulate MDR in human GC cells by targeting
RUNX3.
Human MDR cell line SGC7901/ADR and SGC7901/VCR were
widely used as in vitro models for MDR studies in GC, which was
Fig. 4. miR-106a suppressed drug-induced apoptosis. SGC7901 cells were transfected with miR-106a or the control mimic and incubated with CDDP (A) or 5-FU (B) for 48 h.
The apoptosis percentage of cells was calculated via Flow cytometry. The expression levels of Bcl-2 and Bax were examined 48 h after transfection in SGC7901 cells (C). Data
were obtained in three independent experiments. ⁄P < 0.05, compared with control group.
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stepwise selection. Both mRNA and protein expression proﬁles have
been identiﬁed between SGC7901/VCR and its parental cell line
[21,22]. In this study, we found that miR-106a was increased in
SGC7901/ADR and SGC7901/VCR cells compared with SGC7901
cells. Furthermore, modulation of miR-106a expression by miR-
106a mimic or inhibitor could alter the sensitivity of GC cells to che-
mo-therapeutic drugs, such as ADR, CDDP, and 5-FU. These data
shed light on the molecular network underlying MDR in GC.
P-gp, one of ATP-binding cassette (ABC) transporters, encoded
by MDR1 gene, was increased in GC cell lines and tumors, and
played an essential role in the development of MDR in GC by
increasing the efﬂux of cytotoxic drugs. Inhibition of P-gp expres-
sion was used to reverse MDR [23]. Our results revealed that miR-
106a transfection could remarkably elevate P-gp expression. In
addition, supplement of P-gp inhibitor, verapamil, abrogated the
enhanced ADR increase induced by miR-106a, indicating that P-
gp upregulation might partially account for the effect of miR-
106a on drug efﬂux.MDR also involved the evasion of apoptosis of cancer cells.
Changes in apoptosis might affect the efﬁciency of chemo-thera-
peutic drugs. Our study demonstrated that miR-106a suppressed
the drug-induced apoptosis of GC cells, increasing anti-apoptotic
molecule Bcl2 while inhibiting pro-apoptotic molecule Bax expres-
sion. These results suggested that miR-106a might promote MDR
in GC cells via reducing the susceptibility of cancer cells to
apoptosis.
RUNX3, a downstream effector of the TGF-b family pathway,
has multiple functions and was ﬁrstly found to correlate with the
genesis and progression of GC acting as a tumor suppressor.
RUNX3 played important roles in the regulation of proliferation,
adhesion, and apoptosis. RUNX3-null mice exhibited hyperplasia
of gastric mucosa. Moreover, reduced expression of RUNX3 was
observed in a variety of cancers, such as breast cancer, colorectal
cancer, and glioma [24–26]. In addition, point mutations of RUNX3
were also observed in certain type of human cancers [27]. These
observations suggested that RUNX3 might function as a tumor
suppressor in several human cancers. Guo et al. reported that
Fig. 5. miR-106a modulated MDR by targeting RUNX3. Predicted miR-106a target site in the 30 UTR of RUNX3 mRNA and its mutant were shown (A). SGC7901 cells were
cotransfected with wild-type RUNX3 30 UTR (WT) or the mutated (Mut) luciferase construct and miR-106a or the control mimic for 48 h. Then luciferase activity assay was
measured (B). SGC7901 cells were transfected with miR-106a mimic. Expression of RUNX3 was detected at 48 h after transfection (C). The expression levels of RUNX3 in GC
cells were examined (D). SGC7901 cells were cotransfected with pBK-RUNX3 or the vector control and miR-106a or the control mimic, and incubated with three chemo-
therapeutic drugs for 72 h. MTT assay was used to assess cell viability, and the IC50 values were calculated (E). Data were obtained in three independent experiments.
⁄P < 0.05, ⁄⁄P < 0.01 compared with control group, #P < 0.05, ##P < 0.01 compared with miR-106a mimic treated group.
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therapeutic drugs by inhibiting expression of Bcl-2, MDR-1, and
multidrug resistance protein-1 (MRP-1) [28]. Horiguchi also found
that loss of RUNX3 resulted in gemcitabine resistance in pancreatic
cancer by inducing MRP-1 expression [29]. Our study demon-
strated that miR-106a directly targeted RUNX3 and inhibited
RUNX3 expression. Ectopic expression of RUNX3 in SGC7901 cells
could abolish the effect of miR-106a on the modulation of MDR in
GC cells. These data suggested that miR-106a might modulate MDR
of GC cells partially by targeting RUNX3.
Collectively, our study found that miR-106a, elevated in multi-
drug-resistant GC cell lines, suppressed the sensitivity of GC cells
to chemo-therapeutic drugs by accelerating drug efﬂux and reduc-
ing apoptosis. Moreover, we validated RUNX3 as a target of miR-
106a in GC cells, indicating that miR-106a might modulate MDR
by regulating RUNX3 in GC. This work provided new mechanism
for underlying MDR and might provide future therapeutic strategy
for the treatment of GC.Conﬂict of interest statement
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